Alpha Tau Medical Ltd ( (DRTS) ) just unveiled an update.
On April 2, 2025, Alpha Tau Medical Ltd. announced it received FDA approval to initiate a pilot study for its Alpha DaRT technology targeting recurrent glioblastoma, a highly aggressive brain cancer. This approval marks a significant step for the company, following previous FDA recognitions, and aims to evaluate the feasibility and safety of the treatment in up to ten U.S. patients, potentially enhancing Alpha Tau’s position in the oncology therapeutics market.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of its innovative Alpha DaRT® technology for the treatment of solid tumors. The technology, initially developed by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University, aims to deliver highly potent alpha-radiation directly into tumors.
YTD Price Performance: -19.35%
Average Trading Volume: 92,521
Technical Sentiment Signal: Buy
Current Market Cap: $176.7M
For an in-depth examination of DRTS stock, go to TipRanks’ Stock Analysis page.